Figure 3From: Impact of UGT2B7 His268Tyr polymorphism on the outcome of adjuvant epirubicin treatment in breast cancerKaplan-Meier plots of invasive disease-free survival depending on the UGT2B7His268Tyr genotype in control patients. (a) Patients receiving a combination chemotherapy not containing epirubicin or (b) no adjuvant chemotherapy at all.Back to article page